Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pannier, B.
Right arrow Articles by London, G.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pannier, B.
Right arrow Articles by London, G.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results

B. Pannier, A.P. Guérin, S.J. Marchias and G.M. London1

Service d'Hémodialyse, Hôpital F.H. Manhès, Fleury-Mérogis, France

1 Dr Gérard M. London, Service d'Hémodialyse, Hôpital F.H. Manhes, 8 Grande Rue, 91712, Fleury-Mérogis, France.

Abstract

Epidemiological and clinical studies have shown that cardiovascular disease is a major contributory factor to high morbidity and mortality in patients with end-stage renal disease (ESRD). This exvess mortality is related principally to left ventricular hypertrophy (LVH) and increased arterial stiffness and their interaction. Recent findings have indicated that aortic pulse wave velocity (PWV), a marker of aortic stiffness, is a strong independent predictor or cardiovascular and all-cause mortality in patients with ESRD who are on haemodialysis. Furthermore, it was shown in a therapeutic trial that lack of aortic PWV attenuation despite significant drug-induced reduction in blood pressure was a significant predictor of cardiovascular death in patients with ESRD. Moreover, the absence of PWV attenuation was associated with lack of regression of LVH, which by itself was associated with poor outcome. Controlled trials have also shown that angiotensin-converting enzyme inhibitors are the most efficient drugs for regression of LVH. Moreover, independently of its effects on left ventricular mass and blood perssure, the prescription of the ACE inhibitor perindopril, whether in combination or alone, had a strong and independent beneficial impact on all-cause and cardiovascular survival. After adjustment for all confounding factors, the risk ratio for perindorpil use was 0.19 for all-cause mortality and 0.18 for cardiovascular mortality. These results indicate that, in patients with ESRD, improvement in arterial stiffness and regression of LVH are associated with a better prognosis and that the use of the ACE inhibitor perindopril has a favourable effect on survival that is independent of haemodynamic alterations.

Key Words: Arterial stiffness • Aorta • Cardiovascular risk • End-stage renal disease • Prognosis

References

  1. USRD. Causes of death. United States Renal Data System. Am J Kidney Dis. 1998;32(suppl 1):S81–S88[Medline]
  2. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347–354[Web of Science][Medline]
  3. Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000;14:898–902[CrossRef][Web of Science][Medline]
  4. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1992;47:186–192
  5. Silberberg J, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36:286–290[Web of Science][Medline]
  6. London GM, Parfrey PS. Cardiac disease in chronic uremia: pathogenesis. Adv Ren Replace Ther. 1997;4:194–211[Medline]
  7. London GM, Marchais SJ, Guérin AP, Fabiani F, Métivier F. Cardiovascular function in hemodialysis patients. Grünfeld JP, Bach JF, Funck-Brentano JL, Maxwell MH. Advances in Nephrology. 4th Edition. St. Louis: Mosby-Year Book; 1991. p. 249–273
  8. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125–134[Web of Science][Medline]
  9. Ozkahya M, Ok E, Cirit M, et al. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant. 1998;13:1489–1493[Abstract/Free Full Text]
  10. Fagugli RM, Reboldi G, Quintaliani G, et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis. 2001;38:371–376[Web of Science][Medline]
  11. Ahearn DJ, Maher JF. Heart failure as a complication of hemodialysis fistula. Ann Intern Med. 1972;70:201–204
  12. Rosenthal DS, Braunwald E. Hematological-oncological disorders and heart disease. Braunwald E. Heart Disease: Textbook of Cardiovascular Medicine. 4th Edition. Philadelphia: Saunders; 1992. p. 1786–1808
  13. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61[Web of Science][Medline]
  14. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patientss following correction of anemia with recombinant human erythropoietin. Can J Cardiol. 1990;6:1–4[Web of Science][Medline]
  15. Portoles J, Torralbo A, Martin P, Rodrigo R, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in pre-dialysis patients. Am J Kidney Dis. 1997;29:541–548[Web of Science][Medline]
  16. London GM, Guérin AP, Pannier B, Marchais SJ, Benetos A, Safar ME. Increased systolic pressure in chronic uremia: role of arterial wave reflections. Hypertension. 1992;20:10–19[Abstract/Free Full Text]
  17. Klassen P, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002;287:1548–1555[Abstract/Free Full Text]
  18. Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int. 2002;61:717–726[CrossRef][Web of Science][Medline]
  19. Nichols WW, O'Rourke MF. Vascular impedence. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 4th Edition. London: Edward Arnold; 1998. p. 243–283
  20. London GM, Marchais SJ, Safar ME, et al. Aortic and large artery compliance in end-stage renal disease. Kidney Int. 1990;37:137–142[Web of Science][Medline]
  21. London GM, Guérin AP, Marchais ME, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int. 1996;50:600–608[Web of Science][Medline]
  22. Matsumoto Y, Hamada M, Hiwada K. Aortic distensibility is closely related to progression of left ventricular hypertrophy in patients receiving hemodialysis. Angiology. 2000;51:933–941
  23. Blacher J, Pannier B, Guérin AP, Marchais SJ, Safar ME, London GM. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension. 1998;32:570–574[Abstract/Free Full Text]
  24. Blacher J, Guérin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99:2434–2439[Abstract/Free Full Text]
  25. Laurent S, Boutuoyrie P, Asmar R, et al. Aortic stiffness is and independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–1241[Abstract/Free Full Text]
  26. Guérin AP, London GM, Marchais SJ, Métivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014–1021[Abstract/Free Full Text]
  27. London GM, Pannier B, Guérin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12:2759–2767[Abstract/Free Full Text]
  28. London GM, Pannier B, Guérin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: comparative effects of ACE inhibition and calcium channel blockade. Circulation. 1994;90:2786–2796[Abstract/Free Full Text]
  29. Guérin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stagee renal failure. Circulation. 2001;103:987–992[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pannier, B.
Right arrow Articles by London, G.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pannier, B.
Right arrow Articles by London, G.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?